13,700 Shares in Halozyme Therapeutics, Inc. $HALO Bought by Paradigm Asset Management Co. LLC

Paradigm Asset Management Co. LLC purchased a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 13,700 shares of the biopharmaceutical company’s stock, valued at approximately $713,000.

A number of other institutional investors have also made changes to their positions in HALO. Penserra Capital Management LLC bought a new stake in shares of Halozyme Therapeutics in the 1st quarter worth approximately $125,000. Redhawk Wealth Advisors Inc. grew its position in Halozyme Therapeutics by 14.8% in the second quarter. Redhawk Wealth Advisors Inc. now owns 37,419 shares of the biopharmaceutical company’s stock worth $1,947,000 after buying an additional 4,827 shares during the last quarter. Intech Investment Management LLC lifted its position in shares of Halozyme Therapeutics by 9.9% during the 1st quarter. Intech Investment Management LLC now owns 153,199 shares of the biopharmaceutical company’s stock valued at $9,776,000 after acquiring an additional 13,789 shares during the last quarter. Shelton Wealth Management LLC bought a new stake in shares of Halozyme Therapeutics during the 2nd quarter worth $843,000. Finally, Focus Partners Wealth raised its position in shares of Halozyme Therapeutics by 57.8% during the first quarter. Focus Partners Wealth now owns 120,815 shares of the biopharmaceutical company’s stock worth $7,709,000 after purchasing an additional 44,260 shares during the period. 97.79% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, Director Bernadette Connaughton sold 4,000 shares of the firm’s stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $73.68, for a total value of $294,720.00. Following the transaction, the director owned 46,952 shares of the company’s stock, valued at approximately $3,459,423.36. This trade represents a 7.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $75.35, for a total value of $1,507,000.00. Following the sale, the chief executive officer directly owned 733,719 shares of the company’s stock, valued at approximately $55,285,726.65. This trade represents a 2.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 108,227 shares of company stock valued at $7,779,595. 2.40% of the stock is currently owned by corporate insiders.

Halozyme Therapeutics Trading Down 0.2%

HALO stock opened at $68.24 on Friday. Halozyme Therapeutics, Inc. has a 1-year low of $42.01 and a 1-year high of $79.50. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54. The business’s 50 day moving average is $70.66 and its 200-day moving average is $62.86. The firm has a market cap of $8.02 billion, a P/E ratio of 15.62, a P/E/G ratio of 0.35 and a beta of 1.18.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 EPS for the quarter, beating analysts’ consensus estimates of $1.63 by $0.09. The firm had revenue of $354.26 million for the quarter, compared to analyst estimates of $339.18 million. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The company’s revenue for the quarter was up 22.1% compared to the same quarter last year. During the same period in the previous year, the business earned $1.27 earnings per share. Equities analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Zacks Research downgraded shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Morgan Stanley reduced their price objective on Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating for the company in a research report on Monday, October 20th. Leerink Partnrs raised Halozyme Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 14th. Wall Street Zen lowered Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday. Finally, JPMorgan Chase & Co. lifted their target price on shares of Halozyme Therapeutics from $63.00 to $65.00 and gave the company a “neutral” rating in a research note on Monday, October 27th. Six research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $75.00.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.